Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKAN NASDAQ:INDP NASDAQ:JBIO NASDAQ:MYNZ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKANAkanda$3.63+3.1%$4.00$2.91▼$8.75$1.67M1.61172,085 shs150,674 shsINDPIndaptus Therapeutics$5.40-12.2%$9.15$5.40▼$58.24$7.19M1.276,222 shs23,588 shsJBIOJade Biosciences$7.49-1.7%$8.46$6.57▼$105.00$257.75M1.0499,930 shs50,135 shsMYNZMainz Biomed$1.66-1.8%$1.69$1.30▼$16.04$7.69M0.25113,370 shs35,625 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKANAkanda+3.13%-7.40%+8.56%-8.54%-49.93%INDPIndaptus Therapeutics-12.20%-15.63%-26.03%-44.41%-87.72%JBIOJade Biosciences-1.71%-5.79%+2.74%+748,999,900.00%+748,999,900.00%MYNZMainz Biomed-1.78%+2.47%+16.90%-16.16%-89.44%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKANAkanda0.7194 of 5 stars0.03.00.00.01.51.70.6INDPIndaptus Therapeutics2.7537 of 5 stars3.53.00.00.02.41.70.6JBIOJade Biosciences2.2492 of 5 stars3.50.00.00.03.21.70.0MYNZMainz Biomed2.6406 of 5 stars3.33.00.00.01.30.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKANAkanda 0.00N/AN/AN/AINDPIndaptus Therapeutics 3.00Buy$238.004,307.41% UpsideJBIOJade Biosciences 3.00Buy$16.00113.62% UpsideMYNZMainz Biomed 2.50Moderate Buy$14.00743.37% UpsideCurrent Analyst Ratings BreakdownLatest AKAN, JBIO, MYNZ, and INDP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/14/2025JBIOJade BiosciencesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$17.00 ➝ $18.007/14/2025JBIOJade BiosciencesJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$16.006/16/2025JBIOJade BiosciencesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$14.00(Data available from 9/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKANAkanda$840K1.99N/AN/A$9.37 per share0.39INDPIndaptus TherapeuticsN/AN/AN/AN/A($1.51) per shareN/AJBIOJade BiosciencesN/AN/AN/AN/A$6.18 per shareN/AMYNZMainz Biomed$890K8.54N/AN/A$2.61 per share0.64Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKANAkanda-$4.10MN/A0.00∞N/AN/AN/AN/AN/AINDPIndaptus Therapeutics-$15.02M-$37.66N/AN/AN/AN/A-612.59%-243.78%N/AJBIOJade Biosciences-$69.63M-$30.33N/A∞N/AN/A-51.96%-47.65%N/AMYNZMainz Biomed-$21.65M-$65.60N/AN/AN/AN/AN/AN/AN/ALatest AKAN, JBIO, MYNZ, and INDP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025INDPIndaptus Therapeutics-$0.36-$9.09-$8.73-$9.09N/AN/A8/13/2025Q2 2025JBIOJade Biosciences-$0.43-$0.86-$0.43-$0.86N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKANAkandaN/AN/AN/AN/AN/AINDPIndaptus TherapeuticsN/AN/AN/AN/AN/AJBIOJade BiosciencesN/AN/AN/AN/AN/AMYNZMainz BiomedN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKANAkandaN/A1.391.39INDPIndaptus TherapeuticsN/A0.750.75JBIOJade BiosciencesN/A10.3110.31MYNZMainz Biomed0.141.321.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKANAkanda1.00%INDPIndaptus Therapeutics7.06%JBIOJade BiosciencesN/AMYNZMainz BiomedN/AInsider OwnershipCompanyInsider OwnershipAKANAkanda20.39%INDPIndaptus Therapeutics20.80%JBIOJade Biosciences24.90%MYNZMainz BiomedN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKANAkanda110460,000364,000Not OptionableINDPIndaptus Therapeutics61.11 million877,000Not OptionableJBIOJade Biosciences2032.63 million24.50 millionN/AMYNZMainz Biomed304.58 millionN/ANot OptionableAKAN, JBIO, MYNZ, and INDP HeadlinesRecent News About These CompaniesMainz Biomed Announces Registration of ColoAlert in the United KingdomSeptember 2 at 8:01 AM | globenewswire.comMainz Biomed receives Swiss regulatory approval to market ColoAlertAugust 14, 2025 | msn.comMainz Biomed Receives Swiss Regulatory Approval to Market ColoAlert®August 13, 2025 | globenewswire.comMainz Biomed Announces Pricing of $3.0 Million Follow-On Offering of Ordinary Shares and WarrantsAugust 4, 2025 | globenewswire.comMainz Biomed files to sell 1.47M ordinary unitsJuly 31, 2025 | msn.comEQS-News: Mainz Biomed and CARE Conclude Cooperation Agreement for Joint Care Concept for Health Insurance CompaniesJuly 24, 2025 | finanzen.atFMainz Biomed and CARE Conclude Cooperation Agreement for Joint Care Concept for Health Insurance CompaniesJuly 23, 2025 | globenewswire.comMainz Biomed Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colorectal Cancer Screening and Expansion with Pancreatic Cancer Screening AcquisitionJuly 15, 2025 | globenewswire.comMainz Biomed Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colorectal Cancer Screening and Expansion with Pancreatic Cancer Screening AcquisitionJuly 15, 2025 | globenewswire.comMainz Biomed BV News (MYNZ) - Investing.comJuly 4, 2025 | investing.comMainz Biomed erhält staatliche Förderung für die Entwicklung seines innovativen Tests zur Früherkennung von BauchspeicheldrüsenkrebsJune 25, 2025 | anlegerplus.deAMainz BioMed NV: Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening TestJune 25, 2025 | finanznachrichten.deMainz Biomed BV Aktie | MYNZ Kurs | Realtime - Investing.comJune 25, 2025 | de.investing.comEQS-News: Mainz Biomed erhält staatliche Förderung für die Entwicklung seines innovativen Tests zur Früherkennung von BauchspeicheldrüsenkrebsJune 25, 2025 | boerse.deBMainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening TestJune 25, 2025 | globenewswire.comPromising Advancements in Cancer Diagnostics Propel Mainz Biomed B.V. to a Buy RatingJune 11, 2025 | tipranks.comMainz BioMed NV: Mainz Biomed Initiates Feasibility Study of Biomarker Panel in Pancreatic Cancer ProjectJune 10, 2025 | finanznachrichten.deMainz Biomed startet Machbarkeitsstudie zu Biomarker-Panel im Rahmen seines Projekts zur Behandlung von BauchspeicheldrüsenkrebsJune 10, 2025 | anlegerplus.deAMainz Biomed Initiates Feasibility Study of Biomarker Panel in Pancreatic Cancer ProjectJune 10, 2025 | finance.yahoo.comMainz Biomed Initiates Feasibility Phase for Non-Invasive Pancreatic Cancer Screening Test in PancAlert ProjectJune 10, 2025 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAKAN, JBIO, MYNZ, and INDP Company DescriptionsAkanda NASDAQ:AKAN$3.63 +0.11 (+3.13%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$3.64 +0.01 (+0.28%) As of 09/3/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Akanda Corp., through its subsidiaries, engages in the cultivation, manufacture, and distribution of cannabis products to patients worldwide. It offers medicinal-grade cannabis and cannabis based medical and wellness products. The company was incorporated in 2021 and is headquartered in New Romney, the United Kingdom.Indaptus Therapeutics NASDAQ:INDP$5.40 -0.75 (-12.20%) Closing price 09/3/2025 03:59 PM EasternExtended Trading$5.70 +0.30 (+5.63%) As of 09/3/2025 05:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.Jade Biosciences NASDAQ:JBIO$7.49 -0.13 (-1.71%) As of 09/3/2025 04:00 PM EasternAerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.Mainz Biomed NASDAQ:MYNZ$1.66 -0.03 (-1.78%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$1.72 +0.06 (+3.31%) As of 09/3/2025 04:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Shares Can Hit a Fresh High Before Year-End Why Qualcomm Is Outperforming NVIDIA After Months of Lagging Alphabet Stock Surges After Dodging Harsh Antitrust Remedies Wall Street Punishes Dell's Record Quarter: Why They Are Wrong Taiwan Semiconductor Falls on China News—Buy The Dip? CrowdStrike Tests $412 Support as Options Traders Turn Bullish What to Expect From the Q3 Reporting Season IREN Is Up 186% YTD on AI Pivot—And It’s Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
